Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
HIV/AIDS
Pharma
Gilead's PrEP shows early promise in once-yearly dosing
Once-yearly lenacapavir achieved blood concentrations that exceeded those associated with the strong efficacy that its twice-yearly version showed.
Angus Liu
Mar 11, 2025 2:30pm
GSK’s ViiV plots next steps to fight HIV in Black communities
Feb 7, 2025 1:58pm
Gilead aims to shake up HIV PrEP market with long-acting launch
Aug 9, 2024 11:42am
Gilead’s twice-yearly PrEP drug shows 100% efficacy
Jun 20, 2024 11:45am
'Greedy' GSK is under fire from the AIDS Healthcare Foundation
Mar 18, 2024 12:23pm
GSK's long-acting HIV med beats daily pills in some patients
Feb 21, 2024 2:00am
